Das kaum beachtete Papier von Dara Biosciences scheint endlich seinen Boden gefunden zu haben. Seit gut 3 Wochen ist ein leichter Aufwärtstrend zu erkennen. Werde heute mal mit einer Position einsteigen!
Dara Biosciences - Boden gefunden ?
Beiträge: 18
Zugriffe: 8.086 / Heute: 5
Zugriffe: 8.086 / Heute: 5
|
Werbung
Entdecke die beliebtesten ETFs von SPDR
SPDR S&P U.S. Technology Select Sector UCITS ETF
Perf. 12M: +41,91%
SPDR S&P U.S. Communication Serv. Select Sector UCITS ETF Ac
Perf. 12M: +41,62%
SPDR MSCI World Technology UCITS ETF
Perf. 12M: +39,12%
SPDR MSCI World Communication Services UCITS ETF
Perf. 12M: +38,43%
SPDR MSCI Europe Technology UCITS ETF
Perf. 12M: +32,71%
www.nasdaq.com/symbol/dara/premarket
Aber hier ist was im Busch ,-))
$6 Billion Market Cap winkie Like the Orphan Drug news below!
Look at the 1 month chart accumulation and money flow!
A Decision Soon On KRN5500?
DARA Bio has been developing KRN5500 for almost a decade now. It's one of the last surviving pieces of the old DARA Bio from before new management took over in December 2011 and dramatically shifted the company's focus from mass-market opportunities in diabetes, cancer, and autoimmune disease to the current focus on oncology supportive care. KRN5500 an intravenous semisynthetic derivative of the nucleoside-like antineoplastic antibiotic spicamycin, originally isolated from the bacterium Streptomyces alanosinicus. It has the potential to be a breakthrough, non-opioid medicine for the treatment of neuropathic pain in cancer patients, or more specifically, chronic chemotherapy-induced peripheral neuropathy (CCIPN).
KRN5500 was originally developed by Japan's Kirin Brewery in an effort to identify new anti-cancer agents that induce apoptosis and differentiation of myeloid leukemia cells. The work was performed in collaboration with the Massachusetts General Hospital (MGH), the National Cancer Institute (NCI), and Eastern Cooperative Oncology Group (OTC:ECOG) in the U.S. Preclinical data demonstrated that KRN5500 has significant in vitro activity against human chronic lymphocytic leukemia (CLL) cells, thus providing support for advancement into clinical trials for patients with CLL, as well as those with acute myeloid leukemia (AML) and solid tumors.
Four clinical trials have been conducted in cancer patients, including one in Japan and three in the U.S. A total of 91 patients with solid tumors have been treated with single IV KRN5500 doses of up to 21 mg/m2 and weekly doses of up to 42 mg/m2. Unfortunately, no objective antitumor response was observed at the maximum tolerated dose (MTD) in any of these programs. However, potent neuropathic pain reduction was observed in a significant number of patients. MGH published this data in Clinical Cancer Research in November 2003. An additional analysis of these finds was published in the Journal of Pain and Symptom Management in April 2012.
Based on these findings, KRN5500 was reformulated, specifically to remove excipients that caused gastrointestinal side-effects in the original cancer trials, and development was moved forward in CCIPN. CCIPN is a type of pain that results from nerve damage and is characterized by an abnormal hypersensitivity to innocuous, as well as noxious stimuli. This type of pain is extremely difficult to manage, fails to respond to standard analgesic interventions including opioids, and often worsens over time. There are currently no FDA approved treatments for CCIPN. Given the void in the market and peer-reviewed data supporting potential utility of the drug, the U.S. FDA granted Fast Track status for KRN5500 in CCIPN.
We see CCIPN as a nice market opportunity for DARA Bio. The overall neuropathic pain market is enormous, forecasted to grow to $6 billion by 2015. It is one of the more sought-after markets in the pharmaceutical industry, and Orphan Drug status makes the opportunity even more attractive given the seven years of market exclusivity noted above. Specific to this opportunity, neuropathic pain occurs in 30% of cancer patients, including up to 90% of patients with advanced cancer. The incidence and severity of CCIPN vary considerably for each neurotoxic agent, administered alone or in combination, but for vincristine, cisplatin, oxaliplatin, and paclitaxel, estimates are as high as 70% to 90%. As many as 60% of patients receiving docetaxel and 40% of those treated with carboplatin develop CCIPN.
According to the American Cancer Society, there are an estimated 12 million Americans living with active cancer and some 1.6 million new cases each year. Not all types of cancer results in neuropathic pain, and not all active cancer patients are on chemotherapy. But conservatively, if we assume that half of 30% noted above with neuropathic pain are due to chemotherapy and other neurotoxic agents, the market opportunity for KRN5500 is around 1.8 million patients!
Look at the 1 month chart accumulation and money flow!
A Decision Soon On KRN5500?
DARA Bio has been developing KRN5500 for almost a decade now. It's one of the last surviving pieces of the old DARA Bio from before new management took over in December 2011 and dramatically shifted the company's focus from mass-market opportunities in diabetes, cancer, and autoimmune disease to the current focus on oncology supportive care. KRN5500 an intravenous semisynthetic derivative of the nucleoside-like antineoplastic antibiotic spicamycin, originally isolated from the bacterium Streptomyces alanosinicus. It has the potential to be a breakthrough, non-opioid medicine for the treatment of neuropathic pain in cancer patients, or more specifically, chronic chemotherapy-induced peripheral neuropathy (CCIPN).
KRN5500 was originally developed by Japan's Kirin Brewery in an effort to identify new anti-cancer agents that induce apoptosis and differentiation of myeloid leukemia cells. The work was performed in collaboration with the Massachusetts General Hospital (MGH), the National Cancer Institute (NCI), and Eastern Cooperative Oncology Group (OTC:ECOG) in the U.S. Preclinical data demonstrated that KRN5500 has significant in vitro activity against human chronic lymphocytic leukemia (CLL) cells, thus providing support for advancement into clinical trials for patients with CLL, as well as those with acute myeloid leukemia (AML) and solid tumors.
Four clinical trials have been conducted in cancer patients, including one in Japan and three in the U.S. A total of 91 patients with solid tumors have been treated with single IV KRN5500 doses of up to 21 mg/m2 and weekly doses of up to 42 mg/m2. Unfortunately, no objective antitumor response was observed at the maximum tolerated dose (MTD) in any of these programs. However, potent neuropathic pain reduction was observed in a significant number of patients. MGH published this data in Clinical Cancer Research in November 2003. An additional analysis of these finds was published in the Journal of Pain and Symptom Management in April 2012.
Based on these findings, KRN5500 was reformulated, specifically to remove excipients that caused gastrointestinal side-effects in the original cancer trials, and development was moved forward in CCIPN. CCIPN is a type of pain that results from nerve damage and is characterized by an abnormal hypersensitivity to innocuous, as well as noxious stimuli. This type of pain is extremely difficult to manage, fails to respond to standard analgesic interventions including opioids, and often worsens over time. There are currently no FDA approved treatments for CCIPN. Given the void in the market and peer-reviewed data supporting potential utility of the drug, the U.S. FDA granted Fast Track status for KRN5500 in CCIPN.
We see CCIPN as a nice market opportunity for DARA Bio. The overall neuropathic pain market is enormous, forecasted to grow to $6 billion by 2015. It is one of the more sought-after markets in the pharmaceutical industry, and Orphan Drug status makes the opportunity even more attractive given the seven years of market exclusivity noted above. Specific to this opportunity, neuropathic pain occurs in 30% of cancer patients, including up to 90% of patients with advanced cancer. The incidence and severity of CCIPN vary considerably for each neurotoxic agent, administered alone or in combination, but for vincristine, cisplatin, oxaliplatin, and paclitaxel, estimates are as high as 70% to 90%. As many as 60% of patients receiving docetaxel and 40% of those treated with carboplatin develop CCIPN.
According to the American Cancer Society, there are an estimated 12 million Americans living with active cancer and some 1.6 million new cases each year. Not all types of cancer results in neuropathic pain, and not all active cancer patients are on chemotherapy. But conservatively, if we assume that half of 30% noted above with neuropathic pain are due to chemotherapy and other neurotoxic agents, the market opportunity for KRN5500 is around 1.8 million patients!
#7 sollte man das traden verbieten ggg
(vllt kontrollierst mal jetzt deine stueckzahl)
aber hier gibt es auch boersen techno automatik analysen ,
die nicht mal den resplit bemerken
weil die herausgeber nicht mal lesen,
was sie herausgeben.
DARA Biosciences Inc(NASDAQ:DARA) closed yesterday at $2.85, up469.99%, on volume of over 285,999 shares. DARA went down 17.36% in the last 5 days. DARA average trading volume is 1.70 shares. In the time frame of the last one month, shares of DARAdropped Almost 1.17%. Its market capitalization was $88.29 million.
www.techsonian.com/...daqwin-endocan-corpotcmktsendo/12125276/
(vllt kontrollierst mal jetzt deine stueckzahl)
aber hier gibt es auch boersen techno automatik analysen ,
die nicht mal den resplit bemerken
weil die herausgeber nicht mal lesen,
was sie herausgeben.
DARA Biosciences Inc(NASDAQ:DARA) closed yesterday at $2.85, up469.99%, on volume of over 285,999 shares. DARA went down 17.36% in the last 5 days. DARA average trading volume is 1.70 shares. In the time frame of the last one month, shares of DARAdropped Almost 1.17%. Its market capitalization was $88.29 million.
www.techsonian.com/...daqwin-endocan-corpotcmktsendo/12125276/
...was es doch für Peinlichkeiten gibt! Tsssss.............
Ablaufdatum Onshore kommt immer näher
Nordeling-Lang KZ SemperMM von 40 auf 0,44€ reduziert
Nordeling-Lang KZ SemperMM von 40 auf 0,44€ reduziert
...nach dem Resplit :o)
Falls irgend einer einen Bangster mit Dara-Aktien wegrennen sehen hat, bitte bei mir melden! Irgend jemand hat 80% meiner Aktien geklaut! Dafür sind sie jetzt 5 x + X soviel wert!
Falls irgend einer einen Bangster mit Dara-Aktien wegrennen sehen hat, bitte bei mir melden! Irgend jemand hat 80% meiner Aktien geklaut! Dafür sind sie jetzt 5 x + X soviel wert!
Gelöschter Beitrag.
Einblenden
»
#17 
...bei Nordex haben wir schon uns geld verdient ...und ich glaub das ich schon lange da nichts mehr schreibe da ich damit durch bin...du hast dort Köhler verloren und verkauft bevor der Anstieg da war....arme seele
Neueste Beiträge aus dem Dara Biosciences Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
2 | 17 | Dara Biosciences - Boden gefunden ? | doschauher | Franke | 25.04.21 03:12 | |
| 10 | 546 | A game changer for DARA Bioscience | Chalifmann3 | nejlepsi | 25.04.21 02:34 | |
| 3 | 155 | 14 gute gruende Dara Biosciences zu kaufen | eknarfguckste | brauchmehrkohle | 25.04.21 00:01 |